CBT With VR Based Exposure for Social Anxiety Disorder
EXPOSURE IN VIRTUAL REALITY FOR SOCIAL ANXIETY DISORDER - A Randomized Controlled Superiority Trial Comparing Cognitive Behavioral Therapy With Virtual Reality Based Exposure to Cognitive Behavioral Therapy With in Vivo Exposure.
1 other identifier
interventional
51
1 country
1
Brief Summary
Social Anxiety Disorder (SAD) is classified as a phobic (anxious) disorder in which the patient experiences anxiety in social interactions, during which he or she might be judged or socially evaluated by others. SAD has an estimated lifetime prevalence of 3-13%, but remains under-treated. The recommended psychological treatment for SAD is is the exposure technique imbedded in Cognitive Behavioral Therapy (CBT). Traditionally exposure has taken place either in vivo or through imaginary exposure. In vivo has shown to be most effective, but it is costly and time-consuming and situational elements, such as the reaction of others, are difficult to control. Recently, researchers and clinicians have started to use Virtual Reality (VR) to overcome such difficulties. Compared to traditional methods VR-based Exposure has several advantages mainly based on increased control. Meta-analyzes have found superior effect of CBT with VR-based Exposure compared to imaginary exposure, and similar effects when compared to in vivo exposure, with a recent study finding superior effect of VR-based Exposure compared to in vivo. The current evidence thus supports the clinical efficacy of CBT with VR-based Exposure. However, the meta-analyzes include a total of only six randomized controlled trials (RCTs) and only four of these compare CBT with VR-based Exposure to both an in vivo and a control group. The aims of the current study are to develop a complete program of CBT with VR exposure based on 360° videos for adults suffering from SAD, and to evaluate the treatment effect on SAD symptoms. The study is designed as a three arm RCT comparing 1) a group receiving CBT with VR-based Exposure, 2) a group receiving CBT with in vivo exposure and 3) a group receiving VR relaxation. CBT with VR-based Exposure, will include 360° videos with three different scenarios In Vivo Exposure Therapy consists of role-playing and guided exposure either inside or outside the therapist's office. VR Relaxation Therapy consists of a VR scenario of swimming with dolphins. Treatment will last 10 weeks and there will be a 6 months follow-up. . It is hypothesized that
- CBT with VR-based Exposure will reduce symptoms of SAD
- CBT with VR-based Exposure will be more effective than both CBT with in vivo exposure and VR relaxation therapy at the end of treatment
- An effect on symptom reduction will sustain at the 6 months follow-up
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Dec 2019
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 27, 2019
CompletedFirst Posted
Study publicly available on registry
June 4, 2019
CompletedStudy Start
First participant enrolled
December 1, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
October 26, 2022
CompletedMarch 15, 2023
March 1, 2023
2.3 years
May 27, 2019
March 14, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
change in Social Interaction Anxiety Scale (SIAS)
Severity of Social Anxiety Disorder. SIAS is a measure of anxiety in social interactional situations and consist of 20 items scored 0-4. The total score range from 0-80 with a score higher than 43 indicating that SAD is probable
change from baseline to week 10
Secondary Outcomes (3)
Specific Work for Exposure Applied in Therapy (SWEAT).
week 10
change in EQ-5D-5L
change from baseline to week 10
The Working Alliance Inventory-Short Revised (WAI-SR)
week 10
Study Arms (3)
Virtual Reality Exposure Therapy
EXPERIMENTALVRET will include 360° videos with three scenarios a) riding a bus, b) going to a school cafeteria and c) a job interview. These scenarios were chosen based on clinical experience and frequently reported difficult situations in the literature . The order of the scenarios is jointly decided by the patient and therapist. In the videos the patients can make choices which determine the further course of the exposure scenario. For example, in the bus scenario the information system is out of order. Therefore, the patient has to ask the driver to announce, when they are at a particular stop. Depending on whether or not the patient decides to do so, the video will skip to one of two alternative continuations of the scenario. During the exposures the therapist will also motivate the patient towards acting in ways they consider unacceptable to provoke fear of ridicule, and make the patient act against him or her excessively rigid rules for social interaction to observe the consequences.
In Vivo Exposure Therapy
ACTIVE COMPARATORIn vivo exposure consists of role-playing and guided exposure either inside or outside the therapist's office with active modelling from the therapist in early sessions. Staff members are called upon to conduct exposure. Similarly to the VRET during in vivo exposure the therapist will motivate the patient towards acting in ways they consider unacceptable.
Virtual Reality Relaxation Therapy
PLACEBO COMPARATORVR relaxation therapy will consist of a VR scenario of swimming with dolphins, created by the dolphin swim club (www.thedolphinswimclub.com). Swimming with real wild dolphins has been shown to have a positive effect on anxiety, although not specifically on SAD
Interventions
Treatment will be conducted for 10 consecutive weekly 60 min sessions. In the first two treatment conditions sessions are scheduled as follows: Session one: Building a therapeutic alliance and psycho-education about social anxiety and safety and avoidance behaviors. Session two to four: Cognitive restructuring. Session five to nine: Exposure in either in vivo or VR. Session 10: Relapse prevention. Sessions one to four and ten are identical in the two of three treatment arms.
Eligibility Criteria
You may qualify if:
- Able to comprehend the Danish language
- ≥18 years
- Fulfill the diagnostic criteria for SAD according to ICD-10 (F40.1) or ICD-11 (6B04)
You may not qualify if:
- Previously diagnosed with psychosis, Autism Spectrum Disorder or severe depression.
- Participating in other psychotherapeutic treatments during the study
- Substance dependence disorder
- Severe cyber-sickness (corresponding to driving sickness).
- If on medication, medication must be stable for 6 months prior to the study and during the study (i.e., no change).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Region of Southern Denmarklead
- Universite du Quebec en Outaouaiscollaborator
Study Sites (1)
Centre for Telepsychiatry
Odense, 5000, Denmark
Related Publications (7)
Alonso J, Lepine JP; ESEMeD/MHEDEA 2000 Scientific Committee. Overview of key data from the European Study of the Epidemiology of Mental Disorders (ESEMeD). J Clin Psychiatry. 2007;68 Suppl 2:3-9.
PMID: 17288501BACKGROUNDCraske MG, Stein MB. Anxiety. Lancet. 2016 Dec 17;388(10063):3048-3059. doi: 10.1016/S0140-6736(16)30381-6. Epub 2016 Jun 24.
PMID: 27349358BACKGROUNDStein DJ, Lim CCW, Roest AM, de Jonge P, Aguilar-Gaxiola S, Al-Hamzawi A, Alonso J, Benjet C, Bromet EJ, Bruffaerts R, de Girolamo G, Florescu S, Gureje O, Haro JM, Harris MG, He Y, Hinkov H, Horiguchi I, Hu C, Karam A, Karam EG, Lee S, Lepine JP, Navarro-Mateu F, Pennell BE, Piazza M, Posada-Villa J, Ten Have M, Torres Y, Viana MC, Wojtyniak B, Xavier M, Kessler RC, Scott KM; WHO World Mental Health Survey Collaborators. The cross-national epidemiology of social anxiety disorder: Data from the World Mental Health Survey Initiative. BMC Med. 2017 Jul 31;15(1):143. doi: 10.1186/s12916-017-0889-2.
PMID: 28756776BACKGROUNDStein MB, Stein DJ. Social anxiety disorder. Lancet. 2008 Mar 29;371(9618):1115-25. doi: 10.1016/S0140-6736(08)60488-2.
PMID: 18374843BACKGROUNDKampmann IL, Emmelkamp PM, Morina N. Meta-analysis of technology-assisted interventions for social anxiety disorder. J Anxiety Disord. 2016 Aug;42:71-84. doi: 10.1016/j.janxdis.2016.06.007. Epub 2016 Jun 18.
PMID: 27376634BACKGROUNDBouchard S, Dumoulin S, Robillard G, Guitard T, Klinger E, Forget H, Loranger C, Roucaut FX. Virtual reality compared with in vivo exposure in the treatment of social anxiety disorder: a three-arm randomised controlled trial. Br J Psychiatry. 2017 Apr;210(4):276-283. doi: 10.1192/bjp.bp.116.184234. Epub 2016 Dec 15.
PMID: 27979818BACKGROUNDClemmensen L, Bouchard S, Rasmussen J, Holmberg TT, Nielsen JH, Jepsen JRM, Lichtenstein MB. STUDY PROTOCOL: EXPOSURE IN VIRTUAL REALITY FOR SOCIAL ANXIETY DISORDER - a randomized controlled superiority trial comparing cognitive behavioral therapy with virtual reality based exposure to cognitive behavioral therapy with in vivo exposure. BMC Psychiatry. 2020 Jan 30;20(1):32. doi: 10.1186/s12888-020-2453-4.
PMID: 32000725DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Per Trads Ørskov, PhD
Region of Southern Denmark
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Masking Details
- Assignment will be kept blind for participants and clinicians until the first exposure session.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- PhD
Study Record Dates
First Submitted
May 27, 2019
First Posted
June 4, 2019
Study Start
December 1, 2019
Primary Completion
April 1, 2022
Study Completion
October 26, 2022
Last Updated
March 15, 2023
Record last verified: 2023-03
Data Sharing
- IPD Sharing
- Will not share